A citation-based method for searching scientific literature


List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
60

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
F J Lavalle-González, A Januszewicz, J Davidson, C Tong, R Qiu, W Canovatchel, G Meininger. Diabetologia 2013
349
60

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii,[...]. Cardiovasc Diabetol 2020
34
60

EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats.
Wenbin Zhang, Ajith Welihinda, Jordan Mechanic, Haifeng Ding, Liangcheng Zhu, Yuan Lu, Zhongping Deng, Zelin Sheng, Binhua Lv, Yuanwei Chen,[...]. Pharmacol Res 2011
33
40

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
358
40

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi, Inga Petersohn, Paraskevi Salpea, Belma Malanda, Suvi Karuranga, Nigel Unwin, Stephen Colagiuri, Leonor Guariguata, Ayesha A Motala, Katherine Ogurtsova,[...]. Diabetes Res Clin Pract 2019
40

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
40

A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Masaru Kitazawa, Takashi Katagiri, Hiromi Suzuki, Satoshi Matsunaga, Mayuko H Yamada, Tomoo Ikarashi, Masahiko Yamamoto, Kazuo Furukawa, Midori Iwanaga, Mariko Hatta,[...]. Diabetes Obes Metab 2021
4
50

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Russell Scott, Jerry Morgan, Zachary Zimmer, Raymond L H Lam, Edward A O'Neill, Keith D Kaufman, Samuel S Engel, Annaswamy Raji. Diabetes Obes Metab 2018
16
40

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
40



Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
Andrew S Allegretti, Wenbin Zhang, Wenjiong Zhou, Tara K Thurber, Scott P Rigby, Cynthia Bowman-Stroud, Carlos Trescoli, Pierre Serusclat, Mason W Freeman, Yuan-Di C Halvorsen. Am J Kidney Dis 2019
12
40

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Guntram Schernthaner, Jorge L Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, Gary Meininger. Diabetes Care 2013
366
40

Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension.
Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
58
40

A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes.
Yuan-Di Halvorsen, Geoffrey Walford, Tara Thurber, Heidy Russell, Monica Massaro, Mason W Freeman. Diabetes Obes Metab 2020
3
66

Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection.
Xiao-Xue Zhu, Da-Long Zhu, Xiao-Ying Li, Ya-Lin Li, Xiao-Wei Jin, Tian-Xin Hu, Yu Zhao, Yong-Guo Li, Gui-Yu Zhao, Shuang Ren,[...]. Diabetes Obes Metab 2018
16
20

Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.
Shawn E McCandless, Jack A Yanovski, Jennifer Miller, Cary Fu, Lynne M Bird, Parisa Salehi, Christine L Chan, Diane Stafford, M Jennifer Abuzzahab, David Viskochil,[...]. Diabetes Obes Metab 2017
47
20

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.
Jay S Skyler, George L Bakris, Ezio Bonifacio, Tamara Darsow, Robert H Eckel, Leif Groop, Per-Henrik Groop, Yehuda Handelsman, Richard A Insel, Chantal Mathieu,[...]. Diabetes 2017
202
20

Sotagliflozin: First Global Approval.
Anthony Markham, Susan J Keam. Drugs 2019
16
20

Fibroblast Growth Factor 21-Metabolic Role in Mice and Men.
Harald Staiger, Michaela Keuper, Lucia Berti, Martin Hrabe de Angelis, Hans-Ulrich Häring. Endocr Rev 2017
125
20

The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Pascale Fouqueray, Valdis Pirags, Silvio E Inzucchi, Clifford J Bailey, Guntram Schernthaner, Michaela Diamant, Harold E Lebovitz. Diabetes Care 2013
39
20


G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges.
Kurt Ritter, Christian Buning, Nis Halland, Christoph Pöverlein, Lothar Schwink. J Med Chem 2016
67
20

GLP-1 receptor agonists: differentiation within the class.
Simeon I Taylor. Lancet Diabetes Endocrinol 2018
21
20

Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.
Joseph Proietto, Jaret Malloy, Dongliang Zhuang, Mark Arya, Neale D Cohen, Ferdinandus J de Looze, Christopher Gilfillan, Paul Griffin, Stephen Hall, Thomas Nathow,[...]. Diabetologia 2018
9
20

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
M Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B Buse, Robert J Mentz, Neha J Pagidipati, Juliana C Chan, Stephanie M Gustavson, Nayyar Iqbal,[...]. Lancet Diabetes Endocrinol 2018
287
20

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Kristoffer Gehring, Morten Asser Karsdal, Kim Henriksen. J Pharmacol Exp Ther 2019
12
20

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mary E Rinella, Manal F Abdelmalek, James F Trotter, Angelo H Paredes, Hays L Arnold, Marcelo Kugelmas, Mustafa R Bashir, Mark J Jaros, Lei Ling,[...]. Lancet 2018
222
20

Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus.
Xiaolan Yong, Aidong Wen, Xiangyang Liu, Haiyan Liu, Yan-Ping Liu, Nan Li, Tingting Hu, Ying Chen, Minquan Wang, Lantian Wang,[...]. Clin Drug Investig 2016
6
20

Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites.
Caina Li, Miaomiao Yang, Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Sujuan Sun, Quan Liu, Hao Pan, Shuainan Liu, Yi Huan,[...]. Biochem Pharmacol 2018
12
20

Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond.
Shannon E Mullican, Shamina M Rangwala. Trends Endocrinol Metab 2018
51
20

Non-alcoholic fatty liver disease and diabetes.
Jonathan M Hazlehurst, Conor Woods, Thomas Marjot, Jeremy F Cobbold, Jeremy W Tomlinson. Metabolism 2016
224
20


Oral semaglutide for the treatment of type 2 diabetes.
Maka S Hedrington, Stephen N Davis. Expert Opin Pharmacother 2019
20
20

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
261
20

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
Julio Rosenstock, Christopher H Sorli, Michael E Trautmann, Cristóbal Morales, Ulrich Wendisch, George Dailey, Marcus Hompesch, In Young Choi, Jahoon Kang, John Stewart,[...]. Diabetes Care 2019
12
20

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich, Jenny Y Chien, Haoda Fu, Leonard C Glass, Mark A Deeg, William L Holland, Alexei Kharitonenkov, Thomas Bumol, Holger K Schilske, David E Moller. Cell Metab 2013
541
20




Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
André J Scheen, Nicolas Paquot, Pierre J Lefèbvre. Expert Opin Investig Drugs 2017
35
20


Glucokinase activators for diabetes therapy: May 2010 status report.
Franz M Matschinsky, Bogumil Zelent, Nicolai Doliba, Changhong Li, Jane M Vanderkooi, Ali Naji, Ramakanth Sarabu, Joseph Grimsby. Diabetes Care 2011
63
20

Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Karl Sebastian Johansson, Andreas Brønden, Filip Krag Knop, Mikkel Bring Christensen. Expert Opin Pharmacother 2020
4
25

GLP-1 and Amylin in the Treatment of Obesity.
T Jorsal, J Rungby, F K Knop, T Vilsbøll. Curr Diab Rep 2016
34
20

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.
Erin S Morgan, Li-Jung Tai, Nguyen C Pham, Julia K Overman, Lynnetta M Watts, Anne Smith, Shiangtung W Jung, Martin Gajdošík, Martin Krššák, Michael Krebs,[...]. Diabetes Care 2019
18
20

Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
N B Amin, N Aggarwal, D Pall, G Paragh, W S Denney, V Le, M Riggs, R A Calle. Diabetes Obes Metab 2015
25
20

The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman. Diabetes Obes Metab 2019
33
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.